New
HealthMore in Health→
Phase 3 trials show povorcitinib improves facial repigmentation in vitiligo
Key Takeaways
- STOP-V1 and STOP-V2 enrolled 916 adults with moderate-to-severe nonsegmental vitiligo.
- At week 52, 18.9% of treated participants achieved at least 75% facial VASI improvement in each study.
- Adverse-event rates were similar overall between treatment and placebo groups.
DE
DT Editorial Team··via nature.com